If you are planning to apply for a WDA(H) licence in the UK, you have probably already read the MHRA guidance pages, browsed the process licensing portal, and assumed that filling in the form correctly is most of the battle. It is not. Every year, a meaningful share of wholesale dealer authorisation applications are refused, delayed, or sent back for corrective action, and the reasons rarely come down to a single missing document. They come down to how the business actually operates on the ground versus what the application claims on paper.
This guide goes deep into exactly why the MHRA rejects more WDA(H) applications than most applicants expect, what inspectors are genuinely testing for during a pre-licensing inspection, what the fees and timelines actually look like in 2026, and how to build an application that survives scrutiny the first time. If you are searching for WDA(H) licence application help, MHRA wholesale dealer authorisation consultants, WDA(H) application cost in the UK, or trying to understand the full WDA(H) application process before you submit, this is written for you.
What a WDA(H) Licence Actually Authorises
A Wholesale Dealer’s Authorisation for human medicines, commonly written as WDA(H), is the legal licence that allows a company to procure, hold, supply, or export human medicines to other businesses, not to the public. It is issued and supervised by the MHRA under the Human Medicines Regulations 2012 and is inspected against Good Distribution Practice, or GDP, guidelines.
Without this licence, any business-to-business movement of medicines, even on a small or occasional scale, sits outside the legal supply chain, regardless of how competent the team behind it might be. That distinction matters because a large share of rejected or delayed applications come from businesses that only realised they needed a WDA(H) after they were already trading in a way that required one.
A WDA(H) is typically needed if your business does any of the following:
- Supplies medicines to another pharmacy, clinic, hospital, or care home rather than directly to a patient
- Exports human medicines outside the UK or imports them from another country for onward supply
- Moves stock between separate legal entities within the same group, even sister branches
- Acts as a broker arranging the sale or purchase of medicines without physically holding stock
- Supplies GSL products at a scale that starts to resemble business-to-business trade rather than retail
Many pharmacies, clinics, and importers assume that low volume or “just helping out another pharmacy” does not require a WDA(H). The MHRA disagrees. Any repeated supply that resembles business-to-business trade is likely to trigger the legal requirement to hold the licence, and operating without one can be referred to professional bodies such as the GPhC through the Memorandum of Understanding that exists between MHRA and GPhC. That referral can escalate into a fitness to practise matter, which is a far more serious outcome than a delayed licence application.
The Application Process, Step by Step
Applicants submit through the MHRA Process Licensing Portal, known as the PCL portal, where the online form asks for:
- Company and site details, including registered address and the specific premises being authorised
- The activities being applied for, such as procurement, storage, distribution, import, export, or brokering
- A series of yes or no questions that determine which fee band applies to your application
- Details of the nominated Responsible Person and their qualifications
Once submitted, the PCL team checks the application for completeness and contacts you if documents are missing or anomalies need clarifying. Only once the application is deemed complete does it move to the inspectorate for assessment. If the inspectorate is satisfied on paper, they arrange a site inspection before any licence is granted. Decisions on whether an inspection is required, and how extensive it will be, are made on a case by case basis, driven largely by a Risk Based Inspection, or RBI, model that looks at the compliance history of the site as well as any links to suppliers, customers, or third parties already under MHRA or enforcement scrutiny.
On timelines, MHRA’s own published guidance states that a new WDA(H) application takes up to 90 working days to approve, which in practice works out to roughly four to five months once bank holidays and inspection scheduling are factored in. Variations to an existing licence are quicker, taking anywhere from 30 to 90 working days depending on whether a fresh inspection is triggered. Every round of corrective action following a deficiency adds further weeks, sometimes months, on top of that baseline.
What a WDA(H) Application Actually Costs in 2026
Cost is one of the least discussed parts of this process, and applicants routinely under-budget because they rely on outdated figures. Based on current MHRA fee schedules:
- A reduced application plus full inspection fee for a new WDA(H) sits in the region of £5,128, made up of roughly £992 application fee plus a £4,136 inspection fee
- A reduced application with a reduced inspection fee, applicable to wholesalers handling General Sales List products only, comes in at approximately £3,060, split between a £992 application fee and a £2,068 inspection fee
- Variation fees are charged per submission rather than per individual change, so multiple simultaneous changes to a licence only attract the fee for whichever single change carries the highest rate
- If an application for a wholesale dealer’s licence is withdrawn before inspection takes place, the equivalent inspection fee element is refunded
On top of the direct MHRA fees, businesses need to budget for the cost of preparing the site, temperature mapping, transport validation studies, staff training for the Responsible Person, and any consultancy support brought in to close gaps before submission. Treating the MHRA fee as the total cost of getting licensed is one of the more common budgeting mistakes new applicants make.
Why Applications Actually Get Rejected
This is where most applicants underestimate the process. A rejection rarely happens because a form field was left blank. It happens because the site inspection reveals a gap between what was declared on paper and what is actually happening in the warehouse, the office, and the records.
- A Responsible Person Who Cannot Demonstrate the Role
The single most cited issue in MHRA GDP inspection findings relates to the Responsible Person, or RP. Appointing someone to the RP role who lacks genuine experience managing a Pharmaceutical Quality Management System, or who does not fully understand UK national law and GDP guidelines, is a direct path to rejection. Inspectors are not looking for a name on a form. They test whether the RP:
- Can be contacted at all times, not just during standard office hours
- Personally understands their legal responsibilities rather than delegating understanding to someone else
- Has real authority and budget within the company to run the quality system, not just sign it off
- Can coordinate a recall promptly and explain how supplier and customer checks are actually carried out
Weak RP knowledge or a poorly defined RP role has repeatedly shown up as a leading cause of major deficiencies in MHRA’s own published inspection data.
- Quality Management Systems That Look Good on Paper Only
Quality systems consistently top the list of deficiency categories in MHRA’s inspection data. In one MHRA symposium review covering 1,189 GDP deficiencies across 473 inspections between October 2021 and November 2022, quality system failures clustered heavily in the early chapters of the GDP guideline, ahead of transportation and Responsible Person issues. Common examples inspectors cite include:
- Third-party service contracts that have expired or were never formally signed
- Written procedures that do not exist for activities the company is actually performing day to day
- Records that lack enough detail to reconstruct what actually happened during a receipt, a return, or a complaint
- Self-inspection or internal audit programmes that exist on paper but have not actually been carried out
Inspectors do not simply read your SOP. They follow it into the records it should have generated and check whether the system genuinely works in practice, not just in theory.
- Premises, Cold Chain, and Transport Validation Gaps
Premises suitability, cold chain storage, and transport validation feature repeatedly in MHRA inspector deficiency findings. Applicants often submit before:
- Temperature mapping of the storage area has actually been completed and reviewed
- Transport validation studies covering worst case seasonal conditions have been finished
- Alarm and monitoring systems for refrigerated storage have been tested and calibrated
- Contingency plans for power failure or equipment breakdown have been written and rehearsed
If the site is not demonstrably ready on the day of inspection, the application stalls, and in more serious cases, is refused outright.
- Documentation That Does Not Match Reality
A pattern inspectors flag again and again is documentation describing an idealised process rather than the actual one. If your written procedure says stock is checked against a supplier’s wholesale dealer authorisation before every purchase, but there is no record proving that check happened, that gap becomes a deficiency. MHRA inspections increasingly scrutinise data integrity using the ALCOA+ principles, meaning records must be attributable, legible, contemporaneous, original, and accurate, and must be traceable back to a person and a point in time.
- Weak Bona Fide Supplier and Customer Checks
Wholesale dealers are expected to verify that the businesses they buy from and sell to are themselves properly licensed and legitimate. Weak or missing bona fide checks are a recurring theme in GDP inspection findings and are treated seriously because they connect directly to the risk of falsified medicines entering the UK supply chain.
- Underestimating the Bedding-In Period
A less discussed but genuinely important factor is timing. Businesses that rush from deciding they need a WDA(H) straight into submitting an application, without a proper bedding-in period to close gaps identified in an internal gap analysis, are far more likely to fail inspection. A more realistic approach allows several months to implement the quality management system properly, run it in practice long enough to generate real records, and only then submit the formal application. Applying too early, before the paperwork has a track record behind it, is one of the quietest reasons behind refusals that never get discussed publicly.
The Inspection Outcome and Your Right to Respond
If MHRA proposes to refuse an application, or to grant it on different terms than applied for, the applicant is not simply told no. This is a detail almost nobody covers in enough depth. The licensing authority is legally required to:
- Notify the applicant in writing of its proposal to refuse or vary the licence
- Set out the specific reasons behind that proposal
- Give the applicant a period of not less than 28 days to respond before a final decision is made
This response window is one of the most underused parts of the entire process. Applicants who treat it as a genuine opportunity, submitting corrected procedures, additional evidence, or clarification of misunderstood facts, rather than as a formality, materially improve their chances of the licence being granted rather than refused outright. Too many applicants either miss this window or respond with a generic letter instead of substantive corrective evidence.
Deficiencies raised during inspection are also classified by severity, generally as Critical, Major, or Other. A Major deficiency is one that could result in a product not meeting its marketing authorisation, a significant departure from GDP, or a failure to carry out satisfactory checks, and it is Major deficiencies that most often sit behind a refusal or a delayed grant.
Practical Steps Before You Submit
Based on the pattern of deficiencies above, a realistic pre-submission checklist should include:
- Running an honest internal gap analysis against the current GDP guideline before touching the application form
- Confirming your Responsible Person has documented, verifiable experience, not just a job title change
- Completing temperature mapping and transport validation studies with dated evidence, not just a plan to do them
- Reviewing every third-party contract, supplier agreement, and SOP for expiry dates and factual accuracy
- Testing your bona fide check process on a handful of real transactions before the inspector does
- Building in a bedding-in period of several months rather than applying the moment the paperwork looks complete
- Budgeting for the full fee, inspection, and remediation cost rather than the application fee alone
Given the four to five month processing timeline and the cost of remediation after a failed inspection, getting this right the first time is significantly cheaper than getting it wrong and reapplying.
Where Quality and Vigilance Ltd Fits In
This is exactly the kind of regulatory groundwork that Quality and Vigilance Ltd works on with clients across the UK pharmaceutical and healthcare sector. Beyond its core pharmacovigilance and regulatory affairs work covering EMA, FDA, and MHRA requirements, the team understands how quality management systems, documentation, and Responsible Person readiness need to be built well before a WDA(H) application ever reaches the PCL portal. For businesses preparing a new wholesale dealer authorisation application, varying an existing licence, or trying to close the gap between what their SOPs say and what their records actually prove, getting experienced regulatory guidance early is what separates a smooth MHRA approval from a costly rejection and reapplication cycle. If your business is heading toward a WDA(H) submission this year, it is worth having that conversation with a team that has sat on the regulatory side of these inspections before your application ever leaves the PCL portal.
Get in touch with Quality and Vigilance Ltd today to get your WDA(H) application inspection ready before you submit.